Gan & Lee Pharmaceuticals Co Ltd (stock code: 603087.SH), a global biopharmaceutical company, announced on Wednesday that it has received orphan drug status from the European Medicines Agency (EMA) for the investigational drug GLR2007 intended to treat gliomas neuroepithelial tumours that originate from glial cells in the central nervous system.
The company's present clinical development program for GLR2007, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, is exploring the treatment of advanced solid tumours that has the potential to offer treatment options for clinicians and patients.
The product has received Orphan drug status in the European Union based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products.
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amneal's risperidone extended-release injectable suspension approved by US FDA
Brain+ pilot shows Ayla therapy boosts cognitive outcomes in dementia care
Ascelia Pharma files NDA with FDA for liver imaging drug Orviglance
Biophytis secures EMA clearance to advance Phase 2 obesity trial
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15